In recent years, the development of closed-loop systems providing glucose-responsive algorithm-driven insulin delivery revolutionized the treatment of type 1 diabetes, with ever-growing evidence highlighting their value in improving TIR, especially in the overnight period, without causing an increased risk of hypoglycemia [21,22,23,24,25,26,27]. This evidence concerns the gene INS and Hypoglycemia.